Date: Sep 24, 2012 Source: (
click here to go to the source)
Nanosyn announced today that it has launched a new service based on its proprietary Fragment Based Lead Discovery platform. The service includes identification of fragments with high ligand efficiency; lead generation; lead optimization and further development all the way through manufacturing of commercial APIs. Utilization of the platform allows Nanosyn to offer an integrated and cost effective solution of delivering optimized leads and clinical candidates to its clients. Please contact us for more information.
